Aridis Pharmaceuticals Inc
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin… Read more
Aridis Pharmaceuticals Inc (ARDS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2023: 0.083x
Based on the latest financial reports, Aridis Pharmaceuticals Inc (ARDS) has a cash flow conversion efficiency ratio of 0.083x as of September 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-983.00K) by net assets ($-11.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aridis Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2015–2022)
This chart illustrates how Aridis Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aridis Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aridis Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wen Acquisition Corp Warrant
NASDAQ:WENNW
|
N/A |
|
TOTALENERGIES MARKETING NIGERIA PLC
XNSA:TOTAL
|
N/A |
|
CAP LEASE AVIATION
LSE:CLA
|
-0.046x |
|
COMPAGNIE IMMOBILI
SEM:CIMO
|
N/A |
|
INCITY IMMOB - Dusseldorf Stock Exchang
DU:IC8
|
N/A |
|
EAM SOL
BE:EA2
|
0.008x |
|
A-Frontier Co. Ltd.
KO:036180
|
-0.512x |
|
Ceylon Cold Stores PLC
CM:CCSN0000
|
N/A |
Annual Cash Flow Conversion Efficiency for Aridis Pharmaceuticals Inc (2015–2022)
The table below shows the annual cash flow conversion efficiency of Aridis Pharmaceuticals Inc from 2015 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $-24.23 Million | $-29.13 Million | 1.202x | -26.05% |
| 2021-12-31 | $-14.11 Million | $-22.94 Million | 1.626x | -31.08% |
| 2020-12-31 | $-8.68 Million | $-20.48 Million | 2.359x | +205.11% |
| 2019-12-31 | $3.64 Million | $-8.16 Million | -2.244x | -143.28% |
| 2018-12-31 | $26.31 Million | $-24.27 Million | -0.922x | +39.92% |
| 2017-12-31 | $11.44 Million | $-17.56 Million | -1.535x | -247.20% |
| 2016-12-31 | $13.78 Million | $-6.09 Million | -0.442x | -119.91% |
| 2015-12-31 | $-2.02 Million | $-4.49 Million | 2.221x | -- |